Waldencast (WALD)
NASDAQ:WALD
Top Page
Waldencast
(NASDAQ:WALD)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-0.99% Downside)
Action:ReiteratedDate:04/09/26
The score is held down primarily by weak financial performance—especially persistent negative operating/free cash flow and a sharp deterioration in net losses in 2025—while technicals also point to a sustained downtrend. Valuation provides limited support because losses make the negative P/E hard to interpret and there is no dividend yield.
Positive Factors
Obagi injectables launch
FDA approval and a March 2026 injectables launch expand Obagi into medical aesthetics, diversifying revenue beyond skincare products. This taps higher-margin professional channels and creates durable product-category expansion that can strengthen long-term revenue mix and customer retention.
Negative Factors
Persistent negative cash flow
Negative operating and free cash flow over multiple years means the business is not self-funding and remains dependent on external financing or asset dispositions. Persistent cash burn constrains reinvestment in brands, increases dilution or refinancing risk, and limits long-term margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Obagi injectables launch
FDA approval and a March 2026 injectables launch expand Obagi into medical aesthetics, diversifying revenue beyond skincare products. This taps higher-margin professional channels and creates durable product-category expansion that can strengthen long-term revenue mix and customer retention.
Read all positive factors
Waldencast (WALD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$141.09M
Dividend YieldN/A
Average Volume (3M)145.38K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth14.22%
EPS Growth-141.64%
CountryUS
Employees335
SectorConsumer Defensive
Sector Strength42
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.26
Shares Outstanding118,239,890
10 Day Avg. Volume133,325
30 Day Avg. Volume145,381
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.79
P/FCF Ratio-13.20
Enterprise Value/Market Cap1.75
Enterprise Value/Revenue0.91
Enterprise Value/Gross Profit2.00
Enterprise Value/Ebitda-1.62
Forecast
1Y Price Target
$2.13Price Target Upside110.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$293.25M
Waldencast Business Overview & Revenue Model
Company Description
Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available t...
How the Company Makes Money
Waldencast makes money primarily by selling beauty products through its brand portfolio. Revenue is generated from (1) wholesale sales to retailers and distributors (e.g., beauty specialty retailers, department stores, and international distributi...
Waldencast Earnings Call Summary
Earnings Call Date:May 13, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:May 26, 2026
Earnings Call Sentiment Neutral
The earnings call indicated both progress and challenges. While Waldencast achieved strong adjusted gross profit margins and successful product launches, revenue declined overall, and supply chain disruptions impacted performance. The company remains optimistic about future growth amid macroeconomic pressures.Positive Updates
Strong Adjusted Gross Profit Margin
Achieved an adjusted gross profit margin of 76.4%, representing an increase of 10 basis points year-over-year.
Negative Updates
Overall Revenue Decline
Reported a net revenue of $65.4 million, representing a decline of 4.1% from the first quarter of last year.
Read all updates
Q1-2025 Updates
Positive
Negative
Strong Adjusted Gross Profit Margin
Achieved an adjusted gross profit margin of 76.4%, representing an increase of 10 basis points year-over-year.
Read all positive updates
Company Guidance
In the Waldencast First Quarter 2025 Earnings Call, guidance was provided with an optimistic outlook for the fiscal year, despite some challenges. The company reported a net revenue of $65.4 million, a decline of 4.1% year-over-year, with an adjusted gross profit margin of 76.4% and adjusted EBITDA of $4.4 million, reflecting a margin of 6.7%. Guidance for fiscal 2025 includes targeting mid-teens net revenue growth and an adjusted EBITDA margin in the mid to high-teens. The company anticipates accelerated growth driven by innovations in Milk Makeup and Obagi Medical brands, expansion in digital channels, and improved product availability. Additionally, potential tariff impacts are expected to be manageable, with a low single-digit percent increase in cost of goods sold factored into the guidance.Waldencast Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 272.07M | 273.87M | 218.14M | 166.13M | 142.47M |
| Gross Profit | 123.83M | 131.73M | 141.58M | 39.44M | 87.44M |
| EBITDA | -2.49M | 28.63M | -33.54M | -99.25M | 15.05M |
| Net Income | -229.75M | -42.44M | -89.98M | -116.62M | -19.58M |
Balance Sheet | |||||
| Total Assets | 816.20M | 975.86M | 1.04B | 1.09B | 184.59M |
| Cash, Cash Equivalents and Short-Term Investments | 31.89M | 14.80M | 22.58M | 8.69M | 12.79M |
| Total Debt | 149.01M | 182.11M | 177.72M | 199.25M | 118.86M |
| Total Liabilities | 316.10M | 245.92M | 273.44M | 290.18M | 145.35M |
| Stockholders Equity | 461.88M | 662.32M | 624.63M | 639.24M | 39.24M |
Cash Flow | |||||
| Free Cash Flow | -16.25M | -11.83M | -31.82M | -87.51M | 2.24M |
| Operating Cash Flow | -12.82M | -8.82M | -29.77M | -85.01M | 3.53M |
| Investing Cash Flow | 76.23M | -2.92M | -1.99M | -545.28M | -3.79M |
| Financing Cash Flow | -47.22M | 5.58M | 44.33M | 633.35M | 5.16M |
Waldencast Technical Analysis
Negative
1.01
Price Trends
1.52
Negative
1.76
Negative
1.87
Negative
Market Momentum
-0.17
Negative
39.39
Neutral
52.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WALD, the sentiment is Negative. The current price of 1.01 is below the 20-day moving average (MA) of 1.20, below the 50-day MA of 1.52, and below the 200-day MA of 1.87, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 39.39 is Neutral, neither overbought nor oversold. The STOCH value of 52.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WALD.
Waldencast Risk Analysis
Waldencast disclosed 100 risk factors in its most recent earnings report. Waldencast reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Risks Related to Internal Controls and Financial Reporting Q4, 2023
2.
Risks Relating to our Business Operations and Financial Condition Q4, 2023
3.
Risks Related to the Ownership of our Securities Q4, 2023
Waldencast Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $279.38M | 6.24 | -38.92% | 14.78% | -19.17% | 308.81% | |
68 Neutral | $167.03M | 36.20 | 3.06% | ― | 14.47% | 11.29% | |
66 Neutral | $348.25M | -11.71 | -19.64% | ― | -6.23% | 28.57% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
47 Neutral | $165.91M | -3.15 | -145.86% | ― | -9.86% | 0.87% | |
44 Neutral | $141.09M | -0.93 | -34.75% | ― | 14.22% | -141.64% |
* Consumer Defensive Sector Average
WALD
Waldencast
1.10
-1.54
-58.33%
MKTW
MarketWise
17.40
7.56
76.90%
NRDY
Nerdy
0.88
-0.51
-36.76%
ONTF
ON24
8.10
3.22
65.98%
PERF
Perfect Corp
1.64
-0.12
-6.82%
Waldencast Corporate Events
Waldencast Posts Flat 2025 Results as Obagi Surges, Launches Strategic Review and Deleveraging Drive
Mar 13, 2026
On March 13, 2026, Waldencast reported flat full-year 2025 net revenue of $272.1 million and Adjusted EBITDA of $16.1 million, with Q4 2025 revenue steady at $72.0 million and Adjusted EBITDA of $6.6 million. The quarter saw a net loss of $33.5 mi...
Waldencast Shareholders Back Board Slate and Auditor at January 2026 AGM
Jan 15, 2026
On January 14, 2026, Waldencast plc, a foreign private issuer listed in the United States and headquartered in London, held its annual general meeting of shareholders, with 72.05% of outstanding ordinary shares represented in person or by proxy. A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.